| Literature DB >> 30385580 |
Nick S Laursen1, Robert H E Friesen2, Xueyong Zhu1, Mandy Jongeneelen3, Sven Blokland3, Jan Vermond4, Alida van Eijgen4, Chan Tang3, Harry van Diepen4, Galina Obmolova2, Marijn van der Neut Kolfschoten3, David Zuijdgeest3, Roel Straetemans5, Ryan M B Hoffman1, Travis Nieusma1, Jesper Pallesen1, Hannah L Turner1, Steffen M Bernard1, Andrew B Ward1, Jinquan Luo2, Leo L M Poon6, Anna P Tretiakova7, James M Wilson7, Maria P Limberis7, Ronald Vogels3, Boerries Brandenburg3, Joost A Kolkman8, Ian A Wilson9,10.
Abstract
Broadly neutralizing antibodies against highly variable pathogens have stimulated the design of vaccines and therapeutics. We report the use of diverse camelid single-domain antibodies to influenza virus hemagglutinin to generate multidomain antibodies with impressive breadth and potency. Multidomain antibody MD3606 protects mice against influenza A and B infection when administered intravenously or expressed locally from a recombinant adeno-associated virus vector. Crystal and single-particle electron microscopy structures of these antibodies with hemagglutinins from influenza A and B viruses reveal binding to highly conserved epitopes. Collectively, our findings demonstrate that multidomain antibodies targeting multiple epitopes exhibit enhanced virus cross-reactivity and potency. In combination with adeno-associated virus-mediated gene delivery, they may provide an effective strategy to prevent infection with influenza virus and other highly variable pathogens.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30385580 PMCID: PMC6241527 DOI: 10.1126/science.aaq0620
Source DB: PubMed Journal: Science ISSN: 0036-8075 Impact factor: 47.728